Gliomatosis cerebri: molecular pathology and clinical course.

Abstract

Gliomatosis cerebri is a rare, diffusely growing neuroepithelial tumor characterized by extensive brain infiltration involving more than two cerebral lobes. Among 13 patients with gliomatosis cerebri (median age, 46 years), biopsies showed features of diffuse astrocytoma (n = 4), oligoastrocytoma (n = 1), anaplastic astrocytoma (n = 5), anaplastic oligoastrocytoma (n = 1), or glioblastoma (n = 2). Molecular genetic investigation showed TP53 mutations in three of seven tumors and both PTEN mutation and epidermal growth factor receptor overexpression in one tumor. Amplification of CDK4 or MDM2 or homozygous deletion of CDKN2A was not detected. Three of 10 patients receiving radiotherapy showed a partial response (one patient) or had stable disease (two patients) lasting for more than 1 year. Four of six patients treated with procarbazine, carmustine, vincristine chemotherapy demonstrated partial remission (one patient), minor response (two patients), or stable disease (one patient). Median survival time from diagnosis was 14 months (range, 4-91+ months). Infratentorial involvement was associated with shorter survival. We conclude that (1) the molecular genetic alterations in gliomatosis cerebri resemble those in diffuse astrocytomas; (2) the prognosis of gliomatosis cerebri is variable but for at least 50% of patients as poor as for glioblastoma; and (3) some patients respond to radiotherapy and/or procarbazine, carmustine, vincristine chemotherapy.

• Authors: Ulrich Herrlinger, Jörg Felsberg, Wilhelm Küker, Antje Bornemann, Ludwig Plasswilm, Christiane B Knobbe, Herwig Strik, Wolfgang Wick, Richard Meyermann, Johannes Dichgans, Michael Bamberg, Guido Reifenberger, Michael Weller
• Journal: Annals of neurology (Ann Neurol) Vol. 52 Issue 4 Pg. 390-9 (Oct 2002) ISSN: 0364-5134 [Print] United States
• PMID: 12325066 (Publication Type: Journal Article)

Chemical References

• Cyclin-Dependent Kinase Inhibitor p16
• Genetic Markers
• Nuclear Proteins
• Proto-Oncogene Proteins
• Tumor Suppressor Protein p53
• Tumor Suppressor Proteins
• MDM2 protein, human
• Proto-Oncogene Proteins c-mdm2
• Phosphoric Monoester Hydrolases
• PTEN Phosphohydrolase
• PTEN protein, human

Topics

• Adult
• Aged
• Brain Neoplasms (genetics, mortality, pathology, therapy)
• Cause of Death
• Combined Modality Therapy
• Cyclin-Dependent Kinase Inhibitor p16 (genetics)
• Female
• Genetic Markers
• Humans
• Male
• Middle Aged
• Neoplasms, Neuroepithelial (genetics, mortality, pathology, therapy)
• Nuclear Proteins
• PTEN Phosphohydrolase
• Phosphoric Monoester Hydrolases (genetics)
• Proto-Oncogene Proteins (genetics)
• Proto-Oncogene Proteins c-mdm2
• Tumor Suppressor Protein p53 (genetics)
• Tumor Suppressor Proteins (genetics)